Trade Petros Pharmaceuticals, Inc. - PTPI CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.06 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 0.61 |
| Open | 0.61 |
| 1-Year Change | -85.88% |
| Day's Range | 0.61 - 0.63 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 26, 2024 | 0.61 | 0.00 | 0.00% | 0.61 | 0.63 | 0.61 |
| Apr 25, 2024 | 0.61 | -0.01 | -1.61% | 0.62 | 0.62 | 0.58 |
| Apr 24, 2024 | 0.61 | -0.04 | -6.15% | 0.65 | 0.67 | 0.60 |
| Apr 23, 2024 | 0.65 | 0.00 | 0.00% | 0.65 | 0.67 | 0.61 |
| Apr 22, 2024 | 0.63 | -0.02 | -3.08% | 0.65 | 0.65 | 0.60 |
| Apr 19, 2024 | 0.65 | 0.00 | 0.00% | 0.65 | 0.67 | 0.64 |
| Apr 18, 2024 | 0.66 | 0.00 | 0.00% | 0.66 | 0.68 | 0.63 |
| Apr 17, 2024 | 0.66 | 0.01 | 1.54% | 0.65 | 0.69 | 0.61 |
| Apr 16, 2024 | 0.68 | -0.16 | -19.05% | 0.84 | 0.87 | 0.63 |
| Apr 15, 2024 | 0.76 | -0.03 | -3.80% | 0.79 | 0.79 | 0.71 |
| Apr 12, 2024 | 0.81 | -0.07 | -7.95% | 0.88 | 0.88 | 0.80 |
| Apr 11, 2024 | 0.88 | 0.04 | 4.76% | 0.84 | 0.90 | 0.81 |
| Apr 10, 2024 | 0.86 | 0.00 | 0.00% | 0.86 | 0.86 | 0.79 |
| Apr 9, 2024 | 0.89 | 0.00 | 0.00% | 0.89 | 0.91 | 0.86 |
| Apr 8, 2024 | 0.91 | 0.02 | 2.25% | 0.89 | 0.93 | 0.86 |
| Apr 5, 2024 | 0.91 | 0.00 | 0.00% | 0.91 | 0.93 | 0.90 |
| Apr 4, 2024 | 0.93 | 0.01 | 1.09% | 0.92 | 0.97 | 0.88 |
| Apr 3, 2024 | 0.90 | -0.08 | -8.16% | 0.98 | 0.99 | 0.88 |
| Apr 2, 2024 | 1.04 | -0.14 | -11.86% | 1.18 | 1.18 | 0.98 |
| Apr 1, 2024 | 1.38 | -0.02 | -1.43% | 1.40 | 1.46 | 1.37 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Petros Pharmaceuticals, Inc. Company profile
About Petros Pharmaceuticals Inc
Petros Pharmaceuticals, Inc. is a pharmaceutical company that is focused on men’s health therapeutics with a range of commercial capabilities, including sales, marketing, regulatory and medical affairs, finance, trade relations, pharmacovigilance, market access relations, manufacturing and distribution. Its Stendraas is the United States Food and Drug Administration (FDA) approved phosphodiesterase 5 (PDE-5) inhibitor prescription medication for the treatment of erectile dysfunction (ED) and is the only patent-protected PDE-5 inhibitor on the market. The Company also markets its own line of ED products in the form of vacuum erection device (VED) products through its subsidiaries, Timm Medical, Inc. In addition, its ED products of the Company are committed to identifying and developing other pharmaceuticals to advance men’s health, which is H100, which is the topical formulation candidate for the treatment of acute Peyronie’s disease.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Petros Pharmaceuticals Inc revenues totaled $8.7M. Net loss totaled to $801K.
| Industry: | Biotechnology & Medical Research (NEC) |
1185 Avenue Of The Americas, 3Rd Floor
Suite 570
10036
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024
US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com